Genomic Vision Enters Distribution Agreement with CliniSciences
22 June 2023 - 3:00PM
Business Wire
- Exclusive distribution agreement to accelerate product
commercialization in key European markets
- Agreement provides access to CliniSciences' established
distribution channels, customer base, and direct market presence in
more than 15 European countries
- Agreement reaffirms Genomic Vision's new strategy focused on
drug discovery and bioproduction
Regulatory News:
Genomic Vision (FR0011799907 – GV, – the “Company”), a
Euronext-listed biotechnology company that develops products and
services for the highly accurate characterization of DNA sequences,
is pleased to announce an exclusive European distribution agreement
with CliniSciences.
CliniSciences is a major European distributor of innovative
products and services in Life Science Research with a particular
focus on oncology. CliniSciences and Genomic Vision will work
closely together to leverage their respective resources, industry
knowledge, and customer relationships. The agreement provides
Genomic Vision with the capability to offer its innovative
technology, products, and services across 15 European countries,
extending the reach of its cutting-edge genomic solutions in these
key markets.
The collaboration with CliniSciences directly aligns with
Genomic Vision's refocused strategy. Utilizing CliniSciences'
extensive distribution networks, Genomic Vision is set to broaden
the reach of its genomic solutions. This strategic move will not
only bolster Genomic Vision's ability to enhance bioproduction
standards but also empower the progression of advanced cell and
gene therapies. It underscores Genomic Vision's commitment to
delivering accurate genomic characterization at scale, fostering
innovation and excellence in the field.
Outside of Europe, Genomic Vision will continue to independently
commercialize its products and services. This will enable the
Company to maintain its existing distribution channels and
establish relationships with customers around the world. By
ensuring a seamless experience for the Company’s global customer
base, it can continue to serve researchers, clinicians, and other
stakeholders with the same level of quality and reliability they
have come to expect from Genomic Vision.
Aaron Bensimon, Chief Executive Officer of Genomic Vision,
said: “This partnership with CliniSciences is a decisive move
in advancing Genomic Vision's strategic pivot towards bioproduction
and drug discovery. Our collaboration brings together shared
resources, extensive industry knowledge, and robust customer
relationships to enhance the adoption of Genomic Vision's products
throughout Europe. By tapping into CliniSciences' well-established
distribution channels, we are poised to expand the reach of our
innovative technologies more efficiently. We are optimistic about
the potential this partnership holds and look forward to reporting
on our progress in the future.”
Tushendan Rasiah, Chief Executive Officer of CliniSciences,
commented: "Through this distribution agreement with Genomic
Vision, CliniSciences strengthens its position as a commercial
leader in cutting-edge Life Science Research products and services.
We are excited to augment our product offering in two main areas:
firstly, the quality control of genetically engineered cells for
the production of recombinant proteins, and gene and cell therapy;
and secondly, novel screening tests for oncology drugs such as DDR
drugs, paving the way for personalized medicine.”
ABOUT GENOMIC VISION
GENOMIC VISION is a biotechnology company that develops products
and services for the highly accurate characterization of genome
modifications. We deliver high-quality integrated genomic analysis
solutions to improve quality control and bioproduction standards of
advanced gene therapies at scale. Based on molecular combing
technology and artificial intelligence, The Company provides robust
quantitative measurements needed for high confidence
characterization of transformed cell lines and prediction of cell
line performance, in particular in the context of the
biomanufacturing processes of cell and gene therapies. Genomic
Vision’s molecular combing technology has further applications in
drug development of agents targeting DNA replication and damage
response mechanisms, visualizing DNA replication kinetics and
telomere length maintenance. Genomic Vision, based near Paris in
Bagneux, is a public company listed in compartment C of Euronext’s
regulated market in Paris (Euronext: GV – ISIN: FR0011799907).
For further information, please visit www.genomicvision.com
ABOUT CLINISCIENCES
CliniSciences Group is a European distributor of reagents and
equipment for scientific research and medical diagnosis. They
support more than 350,000 customers on a daily basis through their
130 employees in 15 countries, the majority are scientists, most of
whom hold doctorates in science. CliniSciences has over 40 years’
experience in the field of oncology diagnostics with a wide range
of in vitro diagnostic products manufactured by partners recognized
for the quality of their products. CliniSciences' objective is to
contribute to the development of scientific innovation in the world
by participating in the promotion of inventions from laboratories,
particularly in the field of oncology.
For further information, please visit www.clinisciences.com
Member of the CAC® Mid & Small and
CAC® All-Tradable indices
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business. Such forward-looking statements are based on assumptions
that Genomic Vision considers to be reasonable. However, there can
be no assurance that such forward-looking statements will be
verified, which statements are subject to numerous risks, including
the risks set forth in the “Risk Factors” section of the universal
registration document filed with the AMF on April 28, 2023 under
number D.23-0383, available on the web site of Genomic Vision
(www.genomicvision.com) and to the development of economic
conditions, financial markets and the markets in which Genomic
Vision operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Genomic
Vision or not currently considered material by Genomic Vision. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Genomic Vision
to be materially different from such forward-looking
statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
Genomic Vision has set up a financing line in the form of
convertible notes with warrants (OCABSA) with its Financing
partner.
The shares resulting from the conversion or exercise of the
aforementioned securities will, in general, be sold on the market,
which could create downward pressure on the share price as well as
a dilution.
Shareholders could therefore suffer a loss of their invested
capital due to a significant decrease in the value of the company's
shares. The company has carried out several dilutive financing
operations, and investors are advised to be very careful before
making a decision to invest in the company's securities.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230621112363/en/
Genomic Vision Aaron Bensimon Chairman of the Management
Board Tel.: +33 1 49 08 07 51 investisseurs@genomicvision.com
Ulysse Communication Media Relations Bruno Arabian Tél.: +33
1 42 68 29 70 barabian@ulysse-communication.com Consilium
Strategic Communications International Investor Relations &
Strategic Communications Tel.: +44 (0) 20 3709 5700
GenomicVision@consilium-comms.com NewCap France Investor
Relations & Strategic Communications Tel.: +33 1 44 71 94 94
gv@newcap.eu
Guerrero Ventures (TSXV:GV)
Historical Stock Chart
From Apr 2024 to May 2024
Guerrero Ventures (TSXV:GV)
Historical Stock Chart
From May 2023 to May 2024